Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance

Murray et al, 2015 Molecular Cancer Therapeutics                                          

Link to abstract: http://mct.aacrjournals.org/content/14/9/1975.abstract?sid=b737b689-2fe8-4813-95b7-d36f1bafd756

Protein kinase directed cancer therapies are being used more and more, but have issues with poor clinical response (“innate resistance”) or disease relapse (“acquired or secondary resistance).  Examples of these drugs are: sunitinib, dabrafenib, erlotinib, crizotinib and imatinib. 

*This is a review of intrinsic and extrinsic mechanisms of resistance to these drugs and how drug combination therapy can be used to improve outcomes.